TG Therapeutics Inc (TGTX)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 41,929 | -505 | 101,845 | 48,355 | 20,633 | -18,944 | -168,691 | -162,958 | -192,838 | -233,723 | -283,888 | -322,439 | -344,769 | -338,604 | -339,198 | -312,551 | -273,594 | -224,773 | -199,912 | -184,611 |
| Total assets | US$ in thousands | 577,690 | 586,014 | 401,207 | 373,323 | 329,587 | 331,067 | 220,854 | 197,358 | 193,572 | 217,891 | 251,666 | 303,028 | 379,629 | 409,687 | 481,400 | 548,699 | 625,642 | 273,856 | 294,621 | 101,849 |
| Operating ROA | 7.26% | -0.09% | 25.38% | 12.95% | 6.26% | -5.72% | -76.38% | -82.57% | -99.62% | -107.27% | -112.80% | -106.41% | -90.82% | -82.65% | -70.46% | -56.96% | -43.73% | -82.08% | -67.85% | -181.26% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $41,929K ÷ $577,690K
= 7.26%
The operating return on assets (ROA) of TG Therapeutics Inc has displayed a volatile trend over the analyzed period from March 31, 2020, to December 31, 2024. Initially, the company experienced significantly negative operating ROA figures ranging from -181.26% to -43.73% until December 2020. Subsequently, the values fluctuated but generally remained negative, indicating that the company was not generating sufficient operating income relative to its assets.
There was a slight improvement in the operating ROA in the first half of 2021, with the percentage ranging from -56.96% to -70.46%. However, this was followed by a further decline in the second half of 2021, reaching a low of -90.82% by December 2021. The trend continued to worsen in the first half of 2022, with operating ROA falling to -112.80%.
The turnaround occurred in the second half of 2023, where TG Therapeutics Inc began to show positive operating ROA figures, marking a shift in the company's performance. By December 31, 2023, the operating ROA had increased to 6.26%, signifying that the company was generating operating income from its assets efficiently.
The positive trend continued into 2024, with the operating ROA figures showing further improvement. By June 30, 2024, the operating ROA had increased to 25.38%, indicating that the company was effectively utilizing its assets to generate operating income. There was a slight dip in the operating ROA to -0.09% by September 30, 2024, but it quickly recovered to 7.26% by December 31, 2024.
Overall, the analysis of TG Therapeutics Inc's operating ROA suggests a turnaround in the company's operating efficiency and profitability from the latter half of 2023, with positive trends continuing into 2024.
Peer comparison
Dec 31, 2024